Karyopharm Therapeutics (KPTI) Enterprise Value (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Enterprise Value came in at -$50.9 million in Q4 2025, up 64.76% YoY from -$30.9 million in Q4 2024, and down 16.98% on a QoQ basis from -$43.5 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Enterprise Value (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Enterprise Value data on file, last reported at -$50.9 million in Q4 2025.
- Quarterly Enterprise Value rose 64.76% year-over-year to -$50.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$50.9 million (up 64.76% YoY) and the FY2025 annual result came in at -$50.9 million, up 64.76% from the prior year.
- Enterprise Value eased to -$50.9 million in Q4 2025, from -$43.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$43.5 million in Q3 2025 to a low of -$278.0 million in Q4 2022.
- A 5-year average of -$139.0 million and a median of -$146.5 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value surged 82.14% — and 2022, when it sank 524.57%.
- Tracing KPTI's Enterprise Value over 5 years: stood at -$44.5 million in 2021, then slumped by 524.57% to -$278.0 million in 2022, then surged by 31.13% to -$191.4 million in 2023, then increased by 24.5% to -$144.5 million in 2024, then jumped by 64.76% to -$50.9 million in 2025.
- The last three Enterprise Value figures came in at -$50.9 million (Q4 2025), -$43.5 million (Q3 2025), and -$47.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | -65.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -65.11 Mn |
| Dec 31, 2025 | -50.94 Mn |
| Sep 30, 2025 | -43.55 Mn |
| Jun 30, 2025 | -47.88 Mn |
| Mar 31, 2025 | -85.43 Mn |
| Dec 31, 2024 | -144.53 Mn |
| Sep 30, 2024 | -133.53 Mn |
| Jun 30, 2024 | -152.12 Mn |
| Mar 31, 2024 | -148.58 Mn |
| Dec 31, 2023 | -191.44 Mn |
| Sep 30, 2023 | -165.21 Mn |
| Jun 30, 2023 | -236.77 Mn |
| Mar 31, 2023 | -177.17 Mn |
| Dec 31, 2022 | -277.97 Mn |
| Sep 30, 2022 | -148.38 Mn |
| Jun 30, 2022 | -89.74 Mn |
| Mar 31, 2022 | -205.31 Mn |
| Dec 31, 2021 | -44.51 Mn |
| Sep 30, 2021 | -204.21 Mn |
| Jun 30, 2021 | -95.34 Mn |